- Home
- ONON vs INCY Comparison
ONON vs INCY Comparison
Compare ONON & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONON | INCY |
|---|---|---|
| Founded | 2010 | 1991 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8B | 17.0B |
| IPO Year | 2021 | 1993 |
Fundamental Metrics
Financial Performance| Metric | ONON | INCY |
|---|---|---|
| Price | $48.93 | $94.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 21 |
| Target Price | $62.57 | ★ $94.94 |
| AVG Volume (30 Days) | ★ 7.0M | 2.1M |
| Earning Date | 11-12-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 74.51 | ★ 3878.02 |
| EPS | 0.84 | ★ 5.90 |
| Revenue | $3,607,815,596.00 | ★ $4,813,105,000.00 |
| Revenue This Year | $31.86 | $19.59 |
| Revenue Next Year | $22.90 | $10.88 |
| P/E Ratio | $58.62 | ★ $16.28 |
| Revenue Growth | ★ 33.26 | 18.09 |
| 52 Week Low | $34.38 | $53.56 |
| 52 Week High | $64.05 | $109.28 |
Technical Indicators
Market Signals| Indicator | ONON | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 67.72 | 36.54 |
| Support Level | $45.83 | $94.28 |
| Resistance Level | $48.16 | $96.89 |
| Average True Range (ATR) | 1.70 | 3.12 |
| MACD | 0.50 | -1.51 |
| Stochastic Oscillator | 87.60 | 1.08 |
Price Performance
Historical ComparisonAbout ONON On Holding AG
On Holding AG is a premium performance sports brand rooted in technology, design, and impact. Its shoes, apparel, and accessories products are designed predominantly for athletic use, casual, or leisure purposes. It does not manufacture the products or the raw materials and relies instead on third-party suppliers and contract manufacturers. Geographically, it derives a majority of its revenue from the Americas and rest from Europe, Middle East and Africa and Asia-Pacific region.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.